tbuckley/cabot-search huggingface dataset:
"PUBLIC HEALTH ACTIVITY AND PRIVATE PRACTICE IN VENEREAL DISEASE CONTROL"
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cost-effectiveness of Sofosbuvir-based hepatitis C regimens in Central and West Africa (ANRS 12342)
Authors: S. Boyer, M. Baudoin, M. Nishimwe, M.E. Woode, G. Maradan, M. Lemoine, B. Sylla, C. Kouanfack, P. Carrieri, N. Rouveau, R. Moh, M. Seydi, A. Attia, K. Lacombe
Journal: Journal of Hepatology (2018)
Books Received
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A self-crosslinking, double-functional group modified bacterial cellulose gel used for antibacterial and healing of infected wound
Authors: Yajie Xie, Kun Qiao, Lina Yue, Tao Tang, Yudong Zheng, Shihui Zhu, Huiyi Yang, Ziyuan Fang
Journal: Bioactive Materials (2022)

Cellulose/chitosan composite, as a mature commercial antibacterial dressing, is an important type of wound repair material. However, how to achieve the perfect compound of two components and improve antibacterial activity is a major, lingering issue. In this study, a bifunctional group modified bacterial cellulose (DCBC) was prepared by carboxymethylation and selective oxidation. Further, the chitosan (CS) was compounded in the network of DCBC by self-crosslinking to form dialdehyde carboxymethyl bacterial cellulose/chitosan composites (S-DCBC/CS). The aldehyde group can react with amino of CS by Schiff base reaction. The carboxyl group of DCBC and the amorphous distribution of CS molecular chains increase the antimicrobial properties of composites. The bacteriostatic rate of composites could be higher than 95%. Bacteria can be attracted onto the surface of composites, what we call it "directional adhesion antibacterial effects". In particular, a kind of large animal wound model, deep Ⅱ degree infected scald of Bama miniature pig, was used to research the antimicrobial and healing properties of materials. The S-DCBC/CS can effectively inhibit bacterial proliferation of wound and kill the bacteria. The wound healing rate of S-DCBC/CS was up to 80% after three weeks. The composites show better antibacterial and promoting concrescence effects than traditional chitosan dressings.
Misprescribing analgesics
Authors: J. R. Lewis
Journal: JAMA (1974)

THE abuse of drugs and associated problems are of great concern to physicians, as well as to the public today. Analgesics, including heroin, are the most commonly abused drugs. This commentary is limited to a discussion of the misuse and abuse of analgesic drugs used medically, omitting the larger problem of "street" abuse. Two types of misuse of certain analgesics, overprescribing and underprescribing, have been observed. Overprescribing has resulted in some cases of drug dependence; underprescribing, based on a fear of causing dependence, has led to the inadequate treatment of patients who are in pain. Both types of misuse apparently result from misconceptions or misunderstanding of certain properties of the drugs involved, particularly dependence liability. Therefore, it would be advisable for physicians to reexamine their prescribing practices for analgesics. <h3>Overprescribing</h3> Two analgesics, pentazocine (Talwin) and propoxyphene (Darvon), are not listed under the Controlled Substances Act. Because of this and the
1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
Authors: G. Giaccone, E. Felip, M. Cobo, R. Garcia Campelo, F. DENIS, E. Quoix, A. Madroszyk, D. Debieuvre, W. Hilgers, T. Moran, D. Galetta, G.D. Romano, F. Cappuzzo, G. Robinet, P. Masson, S. Viteri, N. Peled, D. Costantini, R. Dziadziuszko, B. Besse
Journal: Annals of Oncology (2020)
Prophylaxis of Streptococcal Infections and Rheumatic Fever
Authors: Benedict F. Mussell
Journal: JAMA (1979)

Orally administered clindamycin and penicillin were compared for effectiveness in preventing streptococcal infections in 202 randomly assigned patients with previous rheumatic fever (RF). Among 143 patients aged 21 years or younger observed for 537 patient-years, the number of streptococcal infections (and number per patient-year) was 23 (0.084) in the penicillin group and 12 (0.045) in the clindamycin group. Excluding uncooperative patients, the rate of streptococcal infection remained less, though not statistically significant, in the clindamycin group than in the penicillin group. Two RF recurrences occurred in the penicillin group, and no recurrences occurred in the clindamycin group. Clindamycin was well tolerated except for possible mild gastrointestinal symptoms in six patients. Clindamycin can be substituted for penicillin for RF prophylaxis when there is allergy to penicillin or concern about the development of penicillin-resistant mouth organisms. (<i>JAMA</i>241:1589-1594, 1979)
Applied Pharmacology
Authors: Edward J. Walaszek
Journal: JAMA (1969)

The purpose of this revised and rearranged textbook is to present pharmacological principles and to relate these to therapeutics. The first three chapters are devoted to fundamental principles of drug action. The intermediate chapters discuss general and therapeutic pharmacology from the standpoint of normal and abnormal physiology. Concluding chapters deal with principles and special applications of chemotherapy. Rewritten chapters include those dealing with cholinergic and adrenergic transmission, immunopharmacology, psychopharmacology, and chemotherapy. A new chapter on the pharmacology of malignant growth is included. The real merits of this book are its logical organization and skillful presentation. The subject matter is organized according to the physiological system primarily affected. The presentation of each subject is clear and concise. A list at the end of each chapter provides information concerning dose and route of administration of the principal drugs discussed. Concluding each chapter is a pertinent list of references for further reading. This
Progress towards in Vivo Use of siRNAs
Authors: Mark A. Behlke
Journal: Molecular Therapy (2006)

<h2>Abstract</h2> RNA interference (RNAi) has become the method of choice to suppress gene expression <i>in vitro</i>. It is also emerging as a powerful tool for <i>in vivo</i> research with over 90 studies published using synthetic small interfering RNAs in mammals. These reports demonstrate the potential for use of synthetic small interfering RNAs (siRNAs) as therapeutic agents, especially in the areas of cancer and viral infection. The number of reports using siRNAs for functional genomics applications, for validation of targets for small-molecule drug development programs, and to address questions of basic biology will rapidly grow as methods and protocols for use in animals become more established. This review will first discuss aspects of RNAi biochemistry and biology that impact <i>in vivo</i> use, especially as relates to experimental design, and will then provide an overview of published work with a focus on methodology.
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects
Authors: Douglas P. Zipes, Mark S. Link, Michael J. Ackerman, Richard J. Kovacs, Robert J. Myerburg, N.A. Mark Estes
Journal: Journal of the American College of Cardiology (2015)
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics
Authors: Seppo Salminen, Maria Carmen Collado, Akihito Endo, Colin Hill, Sarah Lebeer, Eamonn M. M. Quigley, Mary Ellen Sanders, Raanan Shamir, Jonathan R. Swann, Hania Szajewska, Gabriel Vinderola
Journal: Nature Reviews Gastroenterology & Hepatology (2021)

In 2019, the International Scientific Association for Probiotics and Prebiotics (ISAPP) convened a panel of experts specializing in nutrition, microbial physiology, gastroenterology, paediatrics, food science and microbiology to review the definition and scope of postbiotics. The term 'postbiotics' is increasingly found in the scientific literature and on commercial products, yet is inconsistently used and lacks a clear definition. The purpose of this panel was to consider the scientific, commercial and regulatory parameters encompassing this emerging term, propose a useful definition and thereby establish a foundation for future developments. The panel defined a postbiotic as a "preparation of inanimate microorganisms and/or their components that confers a health benefit on the host". Effective postbiotics must contain inactivated microbial cells or cell components, with or without metabolites, that contribute to observed health benefits. The panel also discussed existing evidence of health-promoting effects of postbiotics, potential mechanisms of action, levels of evidence required to meet the stated definition, safety and implications for stakeholders. The panel determined that a definition of postbiotics is useful so that scientists, clinical triallists, industry, regulators and consumers have common ground for future activity in this area. A generally accepted definition will hopefully lead to regulatory clarity and promote innovation and the development of new postbiotic products.
Left Internal Mammary Artery to Left Anterior Descending Artery. An Alternative for old, High-Risk, Multivessel, Coronary Artery Disease Patients and an Approach for Hybrid Revascularization
Authors: Federico Benetti, Jessica Gonzalez, Natalia Scialacomo
Journal: Clinical Cardiology and Cardiovascular Interventions (2022)

In 1997, the first ambulatory off-pump left internal mammary artery (LIMA) to left anterior descending artery (LAD) anastomosis was performed via xiphoid approach, an intervention known today as the MINI-OPCAB operation. This operation has been performed in more than 150 patients around the world for the management of single and multiple vessel coronary artery disease, and 70 of those cases underwent the procedure in our Foundation from 1997 to 2021, showing no operative mortality or reintervention rates, low conversion rates, early hospital discharge, and 100% graft patency at the follow-ups. The minimally invasive direct coronary artery bypass (MIDCAB) procedure was introduced in 1994 by Benetti from Argentina, and was developed based on our previous experience performing off-pump coronary surgery by manipulating the ascending aorta through a left-sided small thoracotomy. Although it represents one of the most common minimally invasive procedures done worldwide, the original technique is not easy to reproduce, and in most cases the pleura is opened, which increases patients pain, morbidity, hospital length of stay, and hinders the realization of immediate hybrid revascularization after the procedure. The latest minimally invasive approaches for CABG include robotic-assisted procedures, in which the IMAs are harvested using robotic technology or the whole procedure is done using robotic technology. This approach has shown adequate short-term clinical results, however, there are no studies available reporting the procedure’s long-term results. Conclusion: The MINI-OPCAB operation is a friendly approach to perform Minimally Invasive Coronary Bypass Surgery in old, high-risk, multivessel coronary artery disease patients, and it represents a good intervention alternative for the majority of cardiac surgeons and cardiac specialized centers. We also consider this approach as ideal for patients who further require Hybrid Revascularization; however, more experience is needed to validate this initials results.
TACH101, a first-in-class pan-inhibitor of KDM4 for treatment of gastrointestinal cancers.
Authors: Frank Perabo, Chandtip Chandhasin, Sanghee Yoo, Van Dang, Joselyn Del Rosario, Young K Chen, Jeffrey Stafford, Stephen Quake, Michael F. Clarke
Journal: Journal of Clinical Oncology (2022)

132 Background: TACH101 is a novel, potent small molecule inhibitor of KDM4, a novel epigenetic target for cancer therapy. KDM4 is a family of histone lysine demethylases that, when overexpressed, drives key processes linked to cancer. Validation of KDM4 as a driver gene was confirmed across gastrointestinal tumor types including esophageal, colon and gastric cancers, and is associated with formation of aggressive tumors. Methods: TACH101 was evaluated in in vitro and in vivo studies including cell inhibition assays, patient-derived xenograft (PDX) and organoid models, and bioinformatics analyses studies. Results: In vitro, TACH101 treatment potently inhibited cell proliferation in cell lines and organoid models representing esophageal, CRC, and gastric cancers. TACH101 induced apoptosis in human CRC (HT-29) and esophageal (KYSE-150) cancer cell lines (EC50s 0.033 - 0.092 µM). Further evaluation using a panel of &gt; 300 cell lines from different tumor types showed potent activity of TACH101 against gastric cancer and CRC. In gastric cancer, 2D cell viability inhibition assays conducted on a panel of 11 gastric cancer cell lines showed 9/11 (82%) were sensitive to TACH101 treatment (IC50 0.004 - 0.072 µM); in PDX models, 4/5 (80%) were sensitive to TACH101 treatment (IC50 0.007 - 0.039 µM). In CRC, bioinformatics analysis indicated increased TACH101 sensitivity in cell lines with MSI-H status (IC50 1-150 nM). Sensitivity of MSI-H CRC to TACH101 was further confirmed in a panel of 14 CRC PDX models and 7 CRC organoid models in culture-based viability inhibition assays. In PDX models, 5/5 (100%) characterized as MSI were sensitive to TACH101 treatment (IC50 0.001 - 0.014 µM), whereas 4/8 (50%) characterized as MSS were sensitive to TACH101 (IC50 0.003 - 0.270 µM). In patient derived CRC organoid models, 3/3 (100%) characterized as MSI were sensitive to TACH101 treatment (IC50 0.022 - 0.149 µM) whereas 0/3 (0%) characterized as MSS were sensitive (IC50 &gt; 10 µM). In vivo, TACH101 triggered effective tumor control (≥70%) in xenograft models of CRC (SU60), esophageal (KYSE-150) and gastric (GXA-3036) cancers. Pharmacologic studies showed TACH101 demonstrated favorable cell permeability, good oral bioavailability, and high metabolic stability. Conclusions: Preclinical work on TACH101 KDM4 inhibitor demonstrates compelling data and applicability as a potential therapy for gastrointestinal cancers. Preparations to advance TACH101 into clinical trials are underway.
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
Authors: R. Sharon Chinthrajah, Stacie M. Jones, Edwin H. Kim, Scott H. Sicherer, Wayne Shreffler, Bruce J. Lanser, Negin Atri, Denise C. Babineau, Daniel C. Adelman, Ahmar Iqbal, Susan L. Limb, Amanda K. Rudman Spergel, Alkis Togias, Robert A. Wood
Journal: Journal of Allergy and Clinical Immunology (2022)
Correlation of combined positive score of PD-L1 expression and clinical efficacy for advanced esophageal squamous cell carcinoma treated with nivolumab monotherapy.
Authors: Hayato Mikuni, Shun Yamamoto, Ryoichi Sawada, Yoshitaka Honma, Shigeki Sekine, Junya Oguma, Masayuki Saruta, Hiroyuki Daiko, Ken Kato, Koshiro Ishiyama
Journal: Journal of Clinical Oncology (2022)

289 Background: Based on the results of the ATTRACTION-3 trial, nivolumab has shown superiority compared to taxane monotherapy as second-line treatment for advanced esophageal squamous cell carcinoma (ESCC) patients (pts). However, the PD-L1 expression by tumor proportion score (TPS) did not obviously correlate to the efficacy. In contrast, PD-L1 expression by combined positive score (CPS) was used as a companion diagnosis for pembrolizumab in ESCC. There are little data on CPS with nivolumab in ESCC. Methods: We retrospectively reviewed the medical records of the pts with ESCC who received nivolumab monotherapy in our hospital. The CPS before nivolumab was evaluated by 22C3 antibody. We evaluated the correlation of CPS and clinical efficacy of progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR) by using Cox proportional regression model and Fisher’s exact test. Results: Eighty-seven pts were selected for this analysis with a median follow-up time of 7.9 (1.2-84.1) months. Thirty pts (34.5%) had CPS &lt; 10, and 57 patients (65.5%) had CPS≥10. Between two groups, the characteristics were as follows; median age (range): 62 (35-85) and 66 (46-85) years, PS 0: 20.0/36.8%, prior taxane: 50.0/40.4%, prior radiotherapy: 86.7/77.2%, respectively. The median PFS (95%CI) were 1.8 (1.2-2.8)/2.6 (1.8-33.8) months (HR: 0.85 [0.52-1.38], p = 0.50). The ORR/DCR were 21.1/31.6% in CPS &lt; 10 group, and 22.2/57.8% in CPS≥10 group, and there was no statistical significance, respectively (p = 1.0/0.10). In multivariate analysis, only higher age was the favorite factor for PFS. From the result with another cut-off level of CPS, the proportion of CPS≥1/CPS≥20 was 90.8/36.8%. The HR of multivariate analysis with CPS≥1/CPS≥20 was 1.24/0.73, respectively. Conclusions: There was a trend toward better PFS with a higher cut-off point of CPS. CPS had the potential to be a biomarker even for nivolumab for advanced ESCC pts.
WATER, WATER EVERYWHERE AND WHY THE SEA IS SALT
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neonatal Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations
Authors: Myra H. Wyckoff, Jonathan Wyllie, Khalid Aziz, Maria Fernanda de Almeida, Jorge Fabres, Joe Fawke, Ruth Guinsburg, Shigeharu Hosono, Tetsuya Isayama, Vishal S. Kapadia, Han-Suk Kim, Helen G. Liley, Christopher J.D. McKinlay, Lindsay Mildenhall, Jeffrey M. Perlman, Yacov Rabi, Charles C. Roehr, Georg M. Schmölzer, Edgardo Szyld, Daniele Trevisanuto, Sithembiso Velaphi, Gary M. Weiner, Peter G. Davis, Jennifer Dawson, Hege Ersdal, Elizabeth E. Foglia, Mandira Kawakami, Henry C. Lee, Mario Rüdiger, Taylor Sawyer, Amuchou Soraisham, Marya Strand, Enrique Udaeta, Berndt Urlesberger, Nicole K. Yamada, John Madar, Marilyn B. Escobedo, Abhrajit Ganguly, Callum Gately, Beena Kamath-Rayne, Richard Mausling, Jocelyn Domingo-Bates, Firdose Nakwa, Shalini Ramachandran, Jenny Ring, Birju Shah, Christopher Stave, Masanori Tamura, Arjan te Pas, Catherine Cheng, Walid El-Naggar, Emer Finan, Janene Fuerch, Lou Halamek, Omar Kamlin, Satyan Lakshminrusimha, Jane McGowan, Susan Niermeyer, Bin Huey Quek, Nalini Singhal, Daniela Testoni
Journal: Circulation (2020)

This 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations (CoSTR) for neonatal life support includes evidence from 7 systematic reviews, 3 scoping reviews, and 12 evidence updates. The Neonatal Life Support Task Force generally determined by consensus the type of evidence evaluation to perform; the topics for the evidence updates followed consultation with International Liaison Committee on Resuscitation member resuscitation councils. The 2020 CoSTRs for neonatal life support are published either as new statements or, if appropriate, reiterations of existing statements when the task force found they remained valid. Evidence review topics of particular interest include the use of suction in the presence of both clear and meconium-stained amniotic fluid, sustained inflations for initiation of positive-pressure ventilation, initial oxygen concentrations for initiation of resuscitation in both preterm and term infants, use of epinephrine (adrenaline) when ventilation and compressions fail to stabilize the newborn infant, appropriate routes of drug delivery during resuscitation, and consideration of when it is appropriate to redirect resuscitation efforts after significant efforts have failed. All sections of the Neonatal Resuscitation Algorithm are addressed, from preparation through to postresuscitation care. This document now forms the basis for ongoing evidence evaluation and reevaluation, which will be triggered as further evidence is published. Over 140 million babies are born annually worldwide (https://ourworldindata.org/grapher/births-and-deaths-projected-to-2100). If up to 5% receive positive-pressure ventilation, this evidence evaluation is relevant to more than 7 million newborn infants every year. However, in terms of early care of the newborn infant, some of the topics addressed are relevant to every single baby born.